Headache News and Research

Latest Headache News and Research

Genzyme receives FDA approval for Kynamro to treat homozygous familial hypercholesterolemia

The U.S. Food and Drug Administration today approved Kynamro (mipomersen sodium) injection as an addition to lipid-lowering medications and diet to treat patients with a rare type of high cholesterol called homozygous familial hypercholesterolemia (HoFH).

30 Jan 2013

Childhood adversity raises comorbidity risk in bipolar disorder

Childhood adversity, including verbal, physical, or sexual abuse, is associated with the later development of multiple medical comorbidities in patients with bipolar disorder, researchers report.

29 Jan 2013

Sanofi announces availability of Auvi-Q in U.S. retail pharmacies

Sanofi announced today that Auvi-Q (epinephrine injection, USP) is now available in U.S. retail pharmacies nationwide with a prescription from a healthcare provider.

29 Jan 2013

FDA approves Pfizer’s Prevnar 13 to prevent pneumococcal disease in older children, adolescents

Pfizer Inc. announced today that the U.S. Food and Drug Administration (FDA) has granted approval for the expansion of the company's pneumococcal conjugate vaccine, Prevnar 13 (Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein]), for use in older children and adolescents aged 6 years through 17 years for active immunization for the prevention of invasive disease caused by the 13 Streptococcus pneumoniae serotypes contained in the vaccine.

28 Jan 2013

FDA approves Takeda’s NESINA, OSENI and KAZANO for treatment of type 2 diabetes

Takeda Pharmaceutical Company Limited and its wholly-owned subsidiary, Takeda Pharmaceuticals U.S.A., Inc. today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved NESINA (alogliptin) and the fixed-dose combination (FDC) therapies OSENI (alogliptin and pioglitazone) and KAZANO (alogliptin and metformin HCl) for the treatment of type 2 diabetes in adults as adjuncts to diet and exercise.

28 Jan 2013

Takeda receives FDA approval for Nesina, Kazano and Oseni to treat type 2 diabetes

The U.S. Food and Drug Administration today approved three new related products for use with diet and exercise to improve blood sugar control in adults with type 2 diabetes: Nesina (alogliptin) tablets, Kazano (alogliptin and metformin hydrochloride) tablets, and Oseni (alogliptin and pioglitazone) tablets.

28 Jan 2013

Genome sequencing data gives important clues on cancer

Genome sequencing data once regarded as junk is now being used to gain important clues to help understand disease.

25 Jan 2013

Lightning may affect the onset of headache and migraines

University of Cincinnati (UC) researchers have found that lightning may affect the onset of headache and migraines.

25 Jan 2013

Genentech receives FDA approval for new use of Avastin plus chemotherapy to treat mCRC

Genentech, a member of the Roche Group, today announced that the U.S. Food and Drug Administration (FDA) has approved a new use of Avastin (bevacizumab) in combination with fluoropyrimidine-based irinotecan or oxaliplatin chemotherapy for people with metastatic colorectal cancer (mCRC).

23 Jan 2013

Important updates on traumatic brain injury in military personnel

Researchers are making new strides in understanding the health consequences and treatment and rehabilitation needs of combat veterans and other service members affected by traumatic brain injury (TBI).

23 Jan 2013

FDA approves Allergan’s BOTOX to treat overactive bladder

Allergan, Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved BOTOX (onabotulinumtoxinA) for the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency and frequency in adults who have had an inadequate response to or are intolerant of an anticholinergic medication.

19 Jan 2013

Octapharma receives FDA approval for Octaplas to treat blood clotting disorders

The U.S. Food and Drug Administration today approved Octaplas, a pooled plasma (human) blood product for the replacement of clotting proteins (coagulation factors) in certain medical conditions where patients have insufficient levels.

18 Jan 2013

Women who have migraine with aura more likely to develop major cardiovascular events

Women who have migraines with aura, which are often visual disturbances such as flashing lights, may be more likely to have problems with their heart and blood vessels, and those on newer contraceptives may be at higher risk for blood clots, according to two studies released today that will be presented at the American Academy of Neurology's 65th Annual Meeting in San Diego, March 16 to 23, 2013.

17 Jan 2013

Study: Social stigma of chronic migraine and epilepsy are similar

A groundbreaking study lead by William B. Young, MD, a neurologist at Thomas Jefferson University Hospital's Headache Center, shows that patients with migraine (a combination of severe headache, nausea, light sensitivity, and other factors) suffer social stigma from their disease similar to the stigma experienced by patients with epilepsy.

17 Jan 2013

Protein Sciences receives FDA approval for Flublok vaccine

The U.S. Food and Drug Administration today announced that it has approved Flublok, the first trivalent influenza vaccine made using an insect virus (baculovirus) expression system and recombinant DNA technology. Flublok is approved for the prevention of seasonal influenza in people 18 through 49 years of age.

16 Jan 2013

GE Healthcare submits Optison sNDA to aid in detection of cardiovascular diseases

GE Healthcare today announced that it has filed a supplemental new drug application (sNDA) that will allow the company to manufacture Optison (Perflutren Protein-Type A Microspheres Injectable Suspension, USP), within its own facility.

16 Jan 2013

FDA approves Santarus’ UCERIS for induction of remission in patients with ulcerative colitis

Santarus, Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved UCERIS (budesonide) extended release tablets for the induction of remission in patients with active, mild to moderate ulcerative colitis.

16 Jan 2013

Primary-care clinic treatment improves patient follow up

Treating low-acuity emergency-department patients in a primary-care clinic results in better future primary care follow up, research shows.

14 Jan 2013

New research reveals a shared genetic susceptibility to epilepsy and migraine

New research reveals a shared genetic susceptibility to epilepsy and migraine. Findings published in Epilepsia, a journal of the International League Against Epilepsy (ILAE), indicate that having a strong family history of seizure disorders increases the chance of having migraine with aura (MA).

7 Jan 2013

Electroconvulsive therapy releases opiate-like substances

Researchers used electricity on certain regions in the brain of a patient with chronic, severe facial pain to release an opiate-like substance that's considered one of the body's most powerful painkillers.

3 Jan 2013

Headache News and Research

Latest Headache News and Research

Genzyme receives FDA approval for Kynamro to treat homozygous familial hypercholesterolemia

Childhood adversity raises comorbidity risk in bipolar disorder

Sanofi announces availability of Auvi-Q in U.S. retail pharmacies

FDA approves Pfizer’s Prevnar 13 to prevent pneumococcal disease in older children, adolescents

FDA approves Takeda’s NESINA, OSENI and KAZANO for treatment of type 2 diabetes

Takeda receives FDA approval for Nesina, Kazano and Oseni to treat type 2 diabetes

Genome sequencing data gives important clues on cancer

Lightning may affect the onset of headache and migraines

Genentech receives FDA approval for new use of Avastin plus chemotherapy to treat mCRC

Important updates on traumatic brain injury in military personnel

FDA approves Allergan’s BOTOX to treat overactive bladder

Octapharma receives FDA approval for Octaplas to treat blood clotting disorders

Women who have migraine with aura more likely to develop major cardiovascular events

Study: Social stigma of chronic migraine and epilepsy are similar

Protein Sciences receives FDA approval for Flublok vaccine

GE Healthcare submits Optison sNDA to aid in detection of cardiovascular diseases

FDA approves Santarus’ UCERIS for induction of remission in patients with ulcerative colitis

Primary-care clinic treatment improves patient follow up

New research reveals a shared genetic susceptibility to epilepsy and migraine

Electroconvulsive therapy releases opiate-like substances

The future of automation: Machine learning–driven hepatocyte and organoid counting

From street to lab: Advancing controlled substance testing with handheld Raman and FTIR

Reimagining light scattering for biotherapeutics

Headache News and Research

Latest Headache News and Research

The future of automation: Machine learning–driven hepatocyte and organoid counting

From street to lab: Advancing controlled substance testing with handheld Raman and FTIR

Reimagining light scattering for biotherapeutics

Newsletters you may be interested in